{"name": "Chimerix",
 "permalink": "chimerix",
 "crunchbase_url": "http://www.crunchbase.com/company/chimerix",
 "homepage_url": "http://www.chimerix-inc.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2002,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@chimerix-inc.com",
 "phone_number": "(919) 806-1074",
 "description": "Antiviral Therapeutics Developer",
 "created_at": "Tue Aug 11 22:23:23 UTC 2009",
 "updated_at": "Sun Mar 31 09:30:37 UTC 2013",
 "overview": "\u003Cp\u003EChimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.\u003C/p\u003E\n\n\u003Cp\u003EThe company\u00e2\u20ac\u2122s lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug\u00e2\u20ac\u2122s antiviral activity in humans.\u003C/p\u003E\n\n\u003Cp\u003EClinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix\u00e2\u20ac\u2122s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.\u003C/p\u003E\n\n\u003Cp\u003ECMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.\u003C/p\u003E\n\n\u003Cp\u003EChimerix\u00e2\u20ac\u2122s second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.\u003C/p\u003E\n\n\u003Cp\u003ELed by a world-class antiviral drug development team, Chimerix is also leveraging the company\u00e2\u20ac\u2122s extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[148,
       68],
      "assets/images/resized/0005/6041/56041v2-max-150x150.jpg"],
     [[148,
       68],
      "assets/images/resized/0005/6041/56041v2-max-250x250.jpg"],
     [[148,
       68],
      "assets/images/resized/0005/6041/56041v2-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman",
    "person":
     {"first_name": "Ernest",
      "last_name": "Mario",
      "permalink": "ernest-mario-2",
      "image": null}},
   {"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Kenneth",
      "last_name": "I. Moch",
      "permalink": "kenneth-i-moch",
      "image": null}},
   {"is_past": false,
    "title": "Sr. Vice President, CFO",
    "person":
     {"first_name": "Timothy",
      "last_name": "W. Trost",
      "permalink": "timothy-w-trost",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/7048/267048v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7048/267048v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7048/267048v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board Member",
    "person":
     {"first_name": "Artthur",
      "last_name": "M. Pappas",
      "permalink": "artthur-m-pappas",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/7047/267047v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7047/267047v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7047/267047v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board Member",
    "person":
     {"first_name": "Patrick",
      "last_name": "Heron",
      "permalink": "patrick-heron",
      "image":
       {"available_sizes":
         [[[90,
            100],
           "assets/images/resized/0026/4464/264464v1-max-150x150.jpg"],
          [[90,
            100],
           "assets/images/resized/0026/4464/264464v1-max-250x250.jpg"],
          [[90,
            100],
           "assets/images/resized/0026/4464/264464v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board Member",
    "person":
     {"first_name": "Wende",
      "last_name": "Hutton",
      "permalink": "wende-hutton",
      "image":
       {"available_sizes":
         [[[127,
            150],
           "assets/images/resized/0026/0392/260392v1-max-150x150.jpg"],
          [[150,
            176],
           "assets/images/resized/0026/0392/260392v1-max-250x250.jpg"],
          [[150,
            176],
           "assets/images/resized/0026/0392/260392v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$95.2M",
 "funding_rounds":
  [{"round_code": "e",
    "source_url": "http://www.fiercebiotech.com/story/vc-insiders-inject-16m-chimerix/2009-08-11?utm_medium=rss\u0026utm_source=rss\u0026cmp-id=OTC-RSS-FB0",
    "source_description": "VC insiders inject $16M into Chimerix",
    "raised_amount": 16100000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 8,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Canaan Partners",
         "permalink": "canaan-partners-3",
         "image":
          {"available_sizes":
            [[[150,
               49],
              "assets/images/resized/0000/3958/3958v4-max-150x150.jpg"],
             [[250,
               82],
              "assets/images/resized/0000/3958/3958v4-max-250x250.jpg"],
             [[450,
               147],
              "assets/images/resized/0000/3958/3958v4-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Alta Partners",
         "permalink": "alta-partners",
         "image":
          {"available_sizes":
            [[[150,
               22],
              "assets/images/resized/0003/4978/34978v1-max-150x150.png"],
             [[168,
               25],
              "assets/images/resized/0003/4978/34978v1-max-250x250.png"],
             [[168,
               25],
              "assets/images/resized/0003/4978/34978v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Sanderling Ventures",
         "permalink": "sanderling-ventures",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/4787/44787v2-max-150x150.jpg"],
             [[250,
               86],
              "assets/images/resized/0004/4787/44787v2-max-250x250.jpg"],
             [[304,
               105],
              "assets/images/resized/0004/4787/44787v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Asset Management Company",
         "permalink": "asset-management",
         "image":
          {"available_sizes":
            [[[150,
               24],
              "assets/images/resized/0001/9262/19262v1-max-150x150.png"],
             [[250,
               41],
              "assets/images/resized/0001/9262/19262v1-max-250x250.png"],
             [[377,
               62],
              "assets/images/resized/0001/9262/19262v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "c",
    "source_url": "http://www.chimerix-inc.com/news.php?id=8",
    "source_description": "Chimerix Raises $11 Million",
    "raised_amount": 11000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2004,
    "funded_month": 11,
    "funded_day": 4,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Frazier Technology Ventures",
         "permalink": "frazier-technology-ventures",
         "image":
          {"available_sizes":
            [[[150,
               54],
              "assets/images/resized/0001/2344/12344v1-max-150x150.png"],
             [[160,
               58],
              "assets/images/resized/0001/2344/12344v1-max-250x250.png"],
             [[160,
               58],
              "assets/images/resized/0001/2344/12344v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Sanderling Ventures",
         "permalink": "sanderling-ventures",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/4787/44787v2-max-150x150.jpg"],
             [[250,
               86],
              "assets/images/resized/0004/4787/44787v2-max-250x250.jpg"],
             [[304,
               105],
              "assets/images/resized/0004/4787/44787v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Asset Management Company",
         "permalink": "asset-management",
         "image":
          {"available_sizes":
            [[[150,
               24],
              "assets/images/resized/0001/9262/19262v1-max-150x150.png"],
             [[250,
               41],
              "assets/images/resized/0001/9262/19262v1-max-250x250.png"],
             [[377,
               62],
              "assets/images/resized/0001/9262/19262v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "f",
    "source_url": "http://www.chimerix-inc.com/news-and-resources/news-and-resources-details/chimerix-completes-45-million-financing/",
    "source_description": "Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157 ",
    "raised_amount": 45000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 2,
    "funded_day": 14,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "New Leaf Venture Partners",
         "permalink": "new-leaf-venture-partners-2",
         "image":
          {"available_sizes":
            [[[150,
               39],
              "assets/images/resized/0004/2730/42730v1-max-150x150.png"],
             [[250,
               66],
              "assets/images/resized/0004/2730/42730v1-max-250x250.png"],
             [[257,
               68],
              "assets/images/resized/0004/2730/42730v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Pappas Ventures",
         "permalink": "pappas-ventures",
         "image":
          {"available_sizes":
            [[[150,
               131],
              "assets/images/resized/0004/9245/49245v1-max-150x150.png"],
             [[164,
               144],
              "assets/images/resized/0004/9245/49245v1-max-250x250.png"],
             [[164,
               144],
              "assets/images/resized/0004/9245/49245v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Morningside Group",
         "permalink": "morningside-group",
         "image":
          {"available_sizes":
            [[[150,
               25],
              "assets/images/resized/0002/9760/29760v1-max-150x150.png"],
             [[238,
               41],
              "assets/images/resized/0002/9760/29760v1-max-250x250.png"],
             [[238,
               41],
              "assets/images/resized/0002/9760/29760v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Canaan Partners",
         "permalink": "canaan-partners-3",
         "image":
          {"available_sizes":
            [[[150,
               49],
              "assets/images/resized/0000/3958/3958v4-max-150x150.jpg"],
             [[250,
               82],
              "assets/images/resized/0000/3958/3958v4-max-250x250.jpg"],
             [[450,
               147],
              "assets/images/resized/0000/3958/3958v4-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Sanderling Ventures",
         "permalink": "sanderling-ventures",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/4787/44787v2-max-150x150.jpg"],
             [[250,
               86],
              "assets/images/resized/0004/4787/44787v2-max-250x250.jpg"],
             [[304,
               105],
              "assets/images/resized/0004/4787/44787v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Alta Partners",
         "permalink": "alta-partners",
         "image":
          {"available_sizes":
            [[[150,
               22],
              "assets/images/resized/0003/4978/34978v1-max-150x150.png"],
             [[168,
               25],
              "assets/images/resized/0003/4978/34978v1-max-250x250.png"],
             [[168,
               25],
              "assets/images/resized/0003/4978/34978v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Asset Management Company",
         "permalink": "asset-management",
         "image":
          {"available_sizes":
            [[[150,
               24],
              "assets/images/resized/0001/9262/19262v1-max-150x150.png"],
             [[250,
               41],
              "assets/images/resized/0001/9262/19262v1-max-250x250.png"],
             [[377,
               62],
              "assets/images/resized/0001/9262/19262v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Frazier Healthcare Ventures",
         "permalink": "frazier-healthcare-ventures",
         "image":
          {"available_sizes":
            [[[150,
               70],
              "assets/images/resized/0003/2779/32779v1-max-150x150.png"],
             [[153,
               72],
              "assets/images/resized/0003/2779/32779v1-max-250x250.png"],
             [[153,
               72],
              "assets/images/resized/0003/2779/32779v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "d",
    "source_url": "http://www.prnewswire.com/news-releases/chimerix-raises-231-million-to-advance-antiviral-drug-pipeline-58065902.html",
    "source_description": "Chimerix Raises $23.1 Million to Advance Antiviral Drug Pipeline",
    "raised_amount": 23100000.0,
    "raised_currency_code": "USD",
    "funded_year": 2007,
    "funded_month": 2,
    "funded_day": 23,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Canaan Partners",
         "permalink": "canaan-partners-3",
         "image":
          {"available_sizes":
            [[[150,
               49],
              "assets/images/resized/0000/3958/3958v4-max-150x150.jpg"],
             [[250,
               82],
              "assets/images/resized/0000/3958/3958v4-max-250x250.jpg"],
             [[450,
               147],
              "assets/images/resized/0000/3958/3958v4-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Sanderling Ventures",
         "permalink": "sanderling-ventures",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/4787/44787v2-max-150x150.jpg"],
             [[250,
               86],
              "assets/images/resized/0004/4787/44787v2-max-250x250.jpg"],
             [[304,
               105],
              "assets/images/resized/0004/4787/44787v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Asset Management Company",
         "permalink": "asset-management",
         "image":
          {"available_sizes":
            [[[150,
               24],
              "assets/images/resized/0001/9262/19262v1-max-150x150.png"],
             [[250,
               41],
              "assets/images/resized/0001/9262/19262v1-max-250x250.png"],
             [[377,
               62],
              "assets/images/resized/0001/9262/19262v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Frazier Healthcare Ventures",
         "permalink": "frazier-healthcare-ventures",
         "image":
          {"available_sizes":
            [[[150,
               70],
              "assets/images/resized/0003/2779/32779v1-max-150x150.png"],
             [[153,
               72],
              "assets/images/resized/0003/2779/32779v1-max-250x250.png"],
             [[153,
               72],
              "assets/images/resized/0003/2779/32779v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "Headquarters",
    "address1": "2505 Meridian Parkway",
    "address2": "Suite 340",
    "zip_code": "27713",
    "city": "Durham",
    "state_code": "NC",
    "country_code": "USA",
    "latitude": 35.910156,
    "longitude": -78.894591}],
 "milestones":
  [{"description": "Chimerix Awarded BARDA Contract for Advanced Development of Antiviral CMX001 as Medical Countermeasure Against Smallpox\r\n ",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 16,
    "source_url": "http://www.chimerix-inc.com/news-and-resources/news-and-resources-details/barda-contract/",
    "source_text": "",
    "source_description": "Chimerix Awarded BARDA Contract for Advanced Development of Antiviral CMX001 as Medical Countermeasure Against Smallpox  ",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Chimerix",
      "permalink": "chimerix"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}